Navigation Links
Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
Date:3/8/2011

EAST BRUNSWICK, N.J., March 8, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, at 11:00 a.m. Pacific Time.  The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
2. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
3. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
4. Savient Closes Sale of $230 Million in Convertible Senior Notes
5. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
6. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
7. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
8. Savient Pharmaceuticals Announces Search for CEO
9. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... now offer a comprehensive in-house dental plan for all patients. Understanding that budget ... plan that gives patients a number of perks, including discounts on many valuable ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... mental health treatment has announced the opening of a new eating disorder treatment ... and intensive outpatient treatment for adults and adolescents, both males and females ages ...
(Date:11/30/2016)... Warrington, U.K. (PRWEB) , ... November 30, 2016 ... ... to address the tech functions and stylish design wanted by today’s consumers at ... , Cronovo Co-Founder Darin Philip says the new watch is “a game changer” ...
Breaking Medicine News(10 mins):